World-Class Vaccine R&D Facility Opens in Massachusetts

Global biotechnology leader CSL today announced the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts.

CSL's global R&D organization has over 2,000 employees in ten countries, contributing to a robust and promising pipeline of novel therapeutic candidates.

The custom-built facility west of Boston will serve as CSL's central hub for current and future vaccine designs, such as cell-based flu shots.

"CSL's growing R&D presence in Waltham is the latest example of our investment in our future – which includes advancing our growing capabilities in disruptive technologies like next-generation mRNA," said Jon Edelman, Senior Vice President of the CSL Vaccines Innovation Unit, in a press release on March 27, 2023.

In addition to Waltham, Massachusetts, the company has an R&D presence helping create an integrated global organization that can conveniently collaborate with institutions everywhere, offer access to professional development opportunities, and enhance external innovation.

"The Waltham site's location and our investment in this world-class facility will provide our talented people with the ideal environment to deliver the breakthroughs that CSL aims to achieve," added Ethan Settembre, Ph.D., Vice President, Research, CSL Vaccines Innovation Unit and site head for this facility.

"We are also excited that this location provides an opportunity for our scientists to collaborate closely with industry and academic partners, allowing greater access to ongoing innovation and talent."

CSL already produces world-class vaccines, such as Flucelvax® Quadrivalent, a cell culture-based flu vaccine, and bird flu vaccines, such as Audenz™ monovalent, adjuvanted, cell-based inactivated influenza (H5N1) subunit vaccine.

Note: This news article is not paid content.